| Lipids Management |
1 |
1 |
| PCSK9 |
0 |
0.99 |
| Genomic Medicine |
0 |
0.97 |
| Genetics |
0 |
0.98 |
| Statins |
0 |
0.36 |
| Addiction |
0 |
0.17 |
| Alcoholism |
0 |
0.17 |
| Blood-Brain Barrier |
0 |
0.17 |
| Brain |
0 |
0.14 |
| Clinical Research |
0 |
0.14 |
| Cognition |
0 |
0.14 |
| Healthcare and Medical Technology |
0 |
0.14 |
| Alcohol Abuse |
0 |
0.1 |
| Cognitive Impairment |
0 |
0.1 |
| Abuse |
0 |
0.07 |
| Adverse Effects |
0 |
0.07 |
| Biomarker |
0 |
0.07 |
| Blood |
0 |
0.07 |
| Cardiovascular Risk Management |
0 |
0.07 |
| Europe |
0 |
0.07 |
| Impairment |
0 |
0.07 |
| LDL Cholesterol |
0 |
0.07 |
| Memory |
0 |
0.07 |
| Mild Cognitive Impairment |
0 |
0.07 |
| Patient Safety |
0 |
0.07 |